Taltz Patent Protection
6 patents · Eli Lilly and Company
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005713 | Recombinant analog protein with configurable activity | Eli Lilly and Company | Nov 5, 2009 | Nov 4, 2027 | 22 | 1.6y left |
| 10005714 | Therapeutic agent with advanced CMOS mechanism | Eli Lilly and Company | May 12, 2012 | Oct 28, 2028 | 14 | 2.6y left |
| 10005715 | Method for enhanced neural genetic modification | Eli Lilly and Company | Jul 5, 2026 | Sep 14, 2042 | 26 | 16.4y left |
| 10005716 | Novel adaptive nano-scale compound and synthesis thereof | Eli Lilly and Company | Sep 20, 2026 | Mar 9, 2042 | 20 | 15.9y left |
| 10005717 | Therapeutic agent with high-performance AI-driven mechanism | Eli Lilly and Company | Apr 27, 2017 | Apr 15, 2034 | 39 | 8.0y left |
| 10005718 | Medical device for optimized nano-scale delivery | Eli Lilly and Company | May 4, 2013 | May 23, 2031 | 21 | 5.1y left |
For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.